Frees Fund | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

5,000 results for “Frees Fund”

Trials

View all 2391 →

Evaluating a Water Quality Assurance Fund Intervention in Ghana and Kenya

4,800 participants · First posted Aug 26, 2024

Active, not recruiting

Case Studies of Child Care and Development Fund Lead Agencies' Consumer Education Strategies

133 participants · First posted Dec 30, 2024

Not yet recruiting

ITMCTR2200006060

Randomized controlled clinical trial of Gankang granule combined with first-line targeted drugs in the treatment of advanced liver cancer and related mechanisms

Drugs

View all 71 →

RFUSIN2-AML1(Leukemia Research Fund)

FHND-71

FHND-41

Organizations

View all 97 →

Thrasher Research Fund

United States

The Jimmy Fund

United States

NINEPOINT TARGET INCOME FUND

News

View all 2441 →

Rezubio Secures $20 Million Series A to Advance Novel Membrane-Anchored Drug Platform for Obesity and Diabetes

XellSmart Secures Fourth Consecutive FDA and NMPA Approval for iPSC Cell Therapy Targeting Rare Neurodegenerative Disease MSA-P

FDA Approves XellSmart's iPSC-Derived Cell Therapies for Parkinson's Disease and ALS Clinical Trials

Page 1 of 500